Small-molecule-induced polymerization triggers degradation of BCL6
Effective and sustained inhibition of non-enzymatic oncogenic driver proteins is a major
pharmacological challenge. The clinical success of thalidomide analogues demonstrates …
pharmacological challenge. The clinical success of thalidomide analogues demonstrates …
Small-molecule-induced polymerization triggers degradation of BCL6
M Słabicki, H Yoon, J Koeppel, L Nitsch, SSR Burman… - Nature, 2020 - ideas.repec.org
Effective and sustained inhibition of non-enzymatic oncogenic driver proteins is a major
pharmacological challenge. The clinical success of thalidomide analogues demonstrates …
pharmacological challenge. The clinical success of thalidomide analogues demonstrates …
[PDF][PDF] Small molecule-induced polymerization triggers degradation of BCL6
JA Chudasama, PG Miller, C Scholl, S Fröhling… - Nature, 2020 - scholar.archive.org
Effective and sustained inhibition of non-enzymatic oncogenic driver proteins represents a
major pharmacologic challenge. The clinical success of thalidomide analogs demonstrates …
major pharmacologic challenge. The clinical success of thalidomide analogs demonstrates …
Small-molecule-induced polymerization triggers degradation of BCL6
M Słabicki, H Yoon, J Koeppel, L Nitsch… - …, 2020 - ui.adsabs.harvard.edu
Effective and sustained inhibition of non-enzymatic oncogenic driver proteins is a major
pharmacological challenge. The clinical success of thalidomide analogues demonstrates …
pharmacological challenge. The clinical success of thalidomide analogues demonstrates …
Small-molecule-induced polymerization triggers degradation of BCL6
M Sabicki, H Yoon, J Koeppel, L Nitsch, SSR Burman… - paper.sciencenet.cn
Effective and sustained inhibition of non-enzymatic oncogenic driver proteins is a major
pharmacological challenge. The clinical success of thalidomide analogues demonstrates …
pharmacological challenge. The clinical success of thalidomide analogues demonstrates …
Small-molecule-induced polymerization triggers degradation of BCL6
M Słabicki, H Yoon, J Koeppel, L Nitsch, S Roy Burman… - Nature, 2020 - dash.harvard.edu
Effective and sustained inhibition of non-enzymatic oncogenic driver proteins represents a
major pharmacologic challenge. The clinical success of thalidomide analogs demonstrates …
major pharmacologic challenge. The clinical success of thalidomide analogs demonstrates …
Small-molecule-induced polymerization triggers degradation of BCL6
M Słabicki, H Yoon, J Koeppel, L Nitsch… - …, 2020 - pubmed.ncbi.nlm.nih.gov
Effective and sustained inhibition of non-enzymatic oncogenic driver proteins is a major
pharmacological challenge. The clinical success of thalidomide analogues demonstrates …
pharmacological challenge. The clinical success of thalidomide analogues demonstrates …
Small-molecule-induced polymerization triggers degradation of BCL6
M Słabicki, H Yoon, J Koeppel, L Nitsch… - Nature, 2020 - econpapers.repec.org
Effective and sustained inhibition of non-enzymatic oncogenic driver proteins is a major
pharmacological challenge. The clinical success of thalidomide analogues demonstrates …
pharmacological challenge. The clinical success of thalidomide analogues demonstrates …
[PDF][PDF] Small molecule-induced polymerization triggers degradation of BCL6
JA Chudasama, PG Miller, C Scholl, S Fröhling… - Nature, 2020 - marcherin.be
Effective and sustained inhibition of non-enzymatic oncogenic driver proteins represents a
major pharmacologic challenge. The clinical success of thalidomide analogs demonstrates …
major pharmacologic challenge. The clinical success of thalidomide analogs demonstrates …
Small-molecule-induced polymerization triggers degradation of BCL6.
M Słabicki, H Yoon, J Koeppel, L Nitsch, RB SS… - Nature, 2020 - europepmc.org
Effective and sustained inhibition of non-enzymatic oncogenic driver proteins represents a
major pharmacologic challenge. The clinical success of thalidomide analogs demonstrates …
major pharmacologic challenge. The clinical success of thalidomide analogs demonstrates …